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Abstract Conjugated linoleic acid (CLA) is shown to have
chemoprotective properties in various experimental cancer
models. CLA is easily oxidised and it has been suggested that
an increased lipid oxidation may contribute to the antitumori-
genic effects. This report investigates the urinary levels of 8-iso-
PGF2K, a major isoprostane and 15-keto-dihydro-PGF2K, a
major metabolite of PGF2K, as indicators of non-enzymatic and
enzymatic lipid peroxidation after dietary supplementation of
CLA in healthy human subjects for 3 months. A significant
increase of both 8-iso-PGF2K and 15-keto-dihydro-PGF2K in
urine was observed after 3 months of daily CLA intake (4.2
g/day) as compared to the control group (P6 0.0001). Con-
jugated linoleic acid had no effect on the serum K-tocopherol
levels. However, Q-tocopherol levels in the serum increased
significantly (P = 0.015) in the CLA-treated group. Thus, CLA
may induce both non-enzymatic and enzymatic lipid peroxidation
in vivo. Further studies of the mechanism behind, and the possible
consequences of, the increased lipid peroxidation after CLA
supplementation are urgently needed.
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1. Introduction
Conjugated linoleic acid (CLA) is the common denomina-
tion of a group of fatty acids with 18 carbon atoms consisting
of a mixture of positional and geometrical isomers with two
conjugated double bonds, unlike linoleic acid which is a non-
conjugated diene. The two double bonds in CLA are usually
in the C-9 and C-11 or C-10 and C-12 positions and can be in
either the cis or trans con¢guration. CLA is a naturally occur-
ring minor constituent in certain human foods such as rumi-
nant meat and dairy products [1].
Since the early work by Pariza and colleagues on antimuta-
genic and anticarcinogenic properties of CLA several studies
on the bene¢cial e¡ects of CLA have been reported [2,3].
Most of these studies were performed in experimental animals
showing unique inhibitory e¡ects of CLA on mammary gland
cancer, skin cancer and forestomach neoplasia and develop-
ment of body fat content [1^6]. We have recently shown that
the proportion of body fat in humans was reduced after daily
supplementation of CLA for 3 months [7].
Structurally CLA belongs to the family of linoleic acids, the
parent compound of arachidonic acid. Recent studies have
shown that dietary CLA reduces arachidonic acid content
and prostaglandin (PG) E2 biosynthesis in murine keratino-
cytes [8]. Dietary CLA also inhibits phorbol ester-induced
skin tumour promotion and PGE2 production in mouse epi-
dermis [9] and the CLA-induced cytotoxicity in cancer cell
lines is associated with increased lipid oxidation [10,11].
Thus, the availability of CLA in the tissue or circulation
seems to a¡ect the endogenous linoleic acid-related com-
pounds and their metabolites. It is well known that arachi-
donic acid metabolism through non-enzymatic and enzymatic
pathways leads to the formation of isoprostanes and prosta-
glandins that control many physiological and pathophysiolog-
ical consequences of the body [12^19].
We have recently developed highly speci¢c and sensitive
radioimmunoassays (RIA) for 8-iso-PGF2K, a major F2-iso-
prostane, and 15-keto-dihydro-PGF2K, a major metabolite of
PGF2K, as indicators of lipid peroxidation in vivo, through
raising unique antibodies in rabbits [20,21]. The antibodies
discriminate these two very closely related substances which
increase during two di¡erent important biochemical manifes-
tations of lipid peroxidation, namely non-enzymatically and
enzymatically catalysed oxidation of arachidonic acid [22].
The e¡ect of CLA on the lipid peroxidation in humans is
unknown. In this work we have studied the biochemical e¡ect
of CLA on the non-enzymatic and enzymatic lipid peroxida-
tion by measuring both 8-iso-PGF2K and 15-keto-dihydro-
PGF2K in urine, and antioxidant status in serum or plasma
samples, collected from healthy human subjects following
3 months of daily supplement of a mixture of CLA isomers
in a double-blind manner.
2. Materials and methods
2.1. Materials
Unlabelled 8-iso-PGF2K, 15-K-DH-PGF2K and other related iso-
prostanes and prostaglandins were purchased from Cayman Chemi-
cals (Ann Arbor, MI, USA). Tris^HCl, tris-base, EDTA disodium salt
and bovine Q-globulin were purchased from Sigma Chemicals (St.
Louis, MO, USA). Hi-Safe scintillation cocktail was obtained from
Wallac Inc. (Turku, Finland). Polyethylene glycol (MW 4000) was
purchased from Merck (Germany). Tris^HCl bu¡er 0.05 M, pH 7.8
was used in the RIA. Unlabelled 8-iso-PGF2K, 15-K-DH-PGF2K
standards, tritium-labelled tracer and working antibody solution
were prepared in the RIA bu¡er. The tritium-labelled 8-iso-PGF2K
(speci¢c activity: 608 GBq/mmol) was synthesised and puri¢ed as
described previously [20]. The tritium-labelled 15-K-DH-
PGF2K(speci¢c activity: 6.77 TBq/mmol) was obtained from Amer-
sham (Buckinghamshire, UK). Antibodies against both 8-iso-PGF2K
and 15-K-DH-PGF2K were raised at our laboratory and have been
well characterised [20,21]. Carbon tetrachloride was purchased from
Merck, Germany.
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2.2. Experimental protocol
2.2.1. Subjects. Fifty-three healthy men and women aged 23^63
years were included in the study. The participants were randomly
assigned to either a CLA-treated group or a control group before
entering the study. The treatment followed a double-blind fashion.
Some of the baseline data of the two groups are shown in Table 1.
There was no signi¢cant di¡erence between the groups at the begin-
ning of the study. The study plan was approved by the University
Ethics Committee, Medical Faculty, Uppsala University, Sweden.
2.2.2. Study design. All subjects were given control capsules con-
taining olive oil during two initial weeks. The following 12 weeks the
subjects in the CLA group were given capsules containing 4.2 g of
mixed isomers of CLA, mainly consisting of equal amounts of the cis
9 trans 11 and trans 10 cis 12 CLA isomers. The CLA preparation
used in this study contained no isoprostanes or prostaglandins. The
subjects in the control group continued taking olive oil during the
same period of time. The control and CLA capsules were identical
in appearance. The capsules were kindly provided by Natural Ltd.
ASA, Oslo, Norway. The participants were requested not to change
their habits regarding food and physical activity and not to use any
dietary supplements such as vitamins, minerals or fatty acids. Urinary
samples were collected both in the morning and once daily (24 h)
during the initial 2 weeks and during the twelfth week according to
the earlier described method of urinary sample collection [23]. All
samples were stored frozen at 370‡C until analysis.
2.3. Methods
2.3.1. Radioimmunoassay of 8-iso-PGF2K (non-enzymatic lipid
peroxidation indicator). The plasma and urinary samples from this
study were analysed for free 8-iso-PGF2K without any extraction by a
newly developed radioimmunoassay [20]. In brief, an antibody was
raised in rabbits by immunisation with 8-iso-PGF2K coupled to bovine
serum albumin (BSA) at the carboxylic acid by the 1,1P-carbonyldi-
imidazole method. The cross-reactivity of the antibody with 8-iso-15-
keto-13,14-dihydro-PGF2K, 8-iso-PGF2L, PGF2K, 15-keto-PGF2K, 15-
keto-13,14-dihydro-PGF2K, thromboxane (TX) B2, 11L-PGF2K, 9L-
PGF2K and 8-iso-PGF3K was 1.7, 9.8, 1.1, 0.01, 0.01, 0.1, 0.03, 1.8
and 0.6%, respectively. The detection limit of the assay was about
23 pmol/l. The urinary levels of 8-iso-PGF2K were adjusted for crea-
tinine values, which were measured by a commercial kit (IL1 Test by
Monarch Instrument, Amherst, NH, USA).
2.3.2. Radioimmunoassay of 15-keto-dihydro-PGF2K (enzymatic
lipid peroxidation indicator). The urinary samples (24 h) from this
study were also analysed for 15-keto-dihydro-PGF2K without any ex-
traction by a newly developed radioimmunoassay [21]. In brief, an
antibody was raised in rabbits by immunisation with 15-keto-dihy-
dro-PGF2K coupled to BSA at the carboxylic acid by the 1,1P-carbon-
yldiimidazole method. The cross-reactivity of the antibody with
PGF2K, 15-keto-PGF2K, PGE2, 15-keto-13,14-dihydro-PGE2, 8-iso-
15-keto-13,14-dihydro-PGF2K 11L-PGF2K, 9L-PGF2K, TXB2 and
8-iso-PGF3K was 0.02, 0.43, 6 0.001, 0.5, 1.7, 6 0.001, 6 0.001,
6 0.001, 0.01%, respectively. The detection limit of the assay was
about 45 pmol/l. The urinary levels of 15-keto-dihydro-PGF2K were
adjusted for creatinine values.
2.3.3. Measurement of tocopherol. Plasma K- and Q-tocopherol
levels were assayed by using HPLC with £uorescence detection [24].
In brief, 500 Wl plasma was extracted with 500 Wl ethanol containing
0.005% butylated hydroxytoluene and 2 ml hexane. A volume of 20 Wl
of the supernatant was injected to a HPLC column (LiChrospher 100
NH2 250U4 mm). The £uorescence detector had an excitation wave-
length of 295 nm and an emission wavelength of 327 nm. Plasma
tocopherol levels were adjusted for serum lipid concentrations.
2.3.4. Malondialdehyde measurement. Malondialdehyde (MDA), a
product of lipid peroxidation, was measured in plasma as an addi-
tional parameter for comparison with 8-iso-PGF2K measurement by
using a HPLC and £uorescence detector after minor modi¢cation as
described previously [25]. In brief, a thiobarbituric acid reaction was
carried out by mixing 750 Wl of 0.15 M phosphoric acid with 300 Wl of
water and 250 Wl of thiobarbituric acid with 200 Wl plasma sample.
The reaction mixture was incubated in a boiling water bath for 60 min
and then cooled in ice. The MDA^thiobarbituric acid complex was
extracted with methanol and quanti¢ed. A volume of 20 Wl of sample
was injected into the HPLC column. The £uorescence detector had an
excitation wavelength of 532 nm and an emission wavelength of 553
nm. The mobile phase contained methanol:50 mM phosphate bu¡er
(2:3).
2.3.5. Statistical analyses. The results of this investigation were
analysed using the software systems Statistical Analysis System and
STATA (Stata Corporation, TX, USA). For analyses of di¡erences
between the changes in the two treatment groups unpaired t-tests were
used. Variables with a skewed distribution were logarithmically trans-
formed prior to the t-test.
3. Results
This was a double-blind controlled trial in 53 healthy sub-
jects who were treated with CLA (4.2 g/day) or a correspond-
ing amount of a placebo preparation containing olive oil for
3 months. No participant experienced any side e¡ects during
the study period.
3.1. Non-enzymatic lipid peroxidation as assessed by urinary
and plasma F2-isoprostanes
Non-enzymatic lipid peroxidation was assessed by the mea-
surement of one of the major F2-isoprostanes, 8-iso-PGF2K, in
urine samples collected in the morning as well as during 24 h
at the beginning and at the end of this study. Ingestion of
CLA for 3 months resulted in an increase in the basal levels of
both morning and 24 h urinary levels of 8-iso-PGF2K (Table
2). The morning urinary levels of 8-iso-PGF2K increased sig-
ni¢cantly (di¡erence between the changes in the control and
CLA groups, P = 0.0001) to about four times the basal level
(0.47 nmol/mmol creatinine) in these healthy subjects who
were supplemented with CLA for 3 months (Table 2). Simi-
larly, the 24 h urinary 8-iso-PGF2K levels increased
(P6 0.0001) more than three times from the basal level
(0.51 nmol/mmol creatinine) (Table 2). No such increment
in the morning or 24 h urinary 8-iso-PGF2K levels was seen
in the control group (morning urine: before 0.33 and after
0.32 nmol/mmol creatinine; 24 h urine: before 0.34 and after
0.36 nmol/mmol creatinine).
Supplementation of CLA increased plasma 8-iso-PGF2K
levels (CLA group: before 74 þ 10.1 pmol/l (mean þ S.E.M.)
and after 107 þ 15.6 pmol/l) whereas in the control group
there was no change (control group: before 55 þ 6.7 pmol/l
and after 58 þ 10.0 pmol/l) (P = 0.0181 for di¡erence between
changes in the groups). However, the results from only 34 of
the total of 53 subjects could be used in the results because of
technical di⁄culties (many of the heparinised plasma samples
were haemolysed and haemolysed samples cannot be assayed
by this RIA).
3.2. Enzymatic lipid peroxidation as assessed by urinary
15-keto-dihydro-PGF2K
Enzymatic lipid peroxidation was assessed by the measure-
ment of 15-keto-dihydro-PGF2K in 24 h urine samples. The
urinary levels of 15-keto-dihydro-PGF2K increased signi¢-
cantly (P6 0.0001) from the basal level (0.70 nmol/mmol cre-
Table 1
The baseline values of the healthy human subjects included in this
study given as mean (S.D.)
Age (years) 45.4 (11.7)
Sex (men/women) 27/26
Weight (kg) 75.7 (15.3)
BMI (kg/m2) 25.1 (4.1)
Serum TAG (mmol/l) 1.39 (0.77)
Serum cholesterol (mmol/l) 5.60 (1.07)
BMI = body mass index, TAG = triacylglycerides.
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atinine) and were approximately doubled in the subjects who
were supplemented with CLA for 3 months (Table 2). No
such increment in the urinary 15-keto-dihydro-PGF2K levels
was seen in the control group (before 0.51 and after 0.54
nmol/mmol creatinine). The individual changes in the concen-
trations of 15-keto-dihydro-PGF2K in the urine were signi¢-
cantly correlated with those of urinary 8-iso-PGF2K (r = 0.46,
P = 0.0006).
3.3. MDA levels in plasma
No signi¢cant di¡erence in changes of the MDA levels in
plasma was seen in the CLA (before 0.60 and after 0.56 Wmol/
l) or in the control group (before 0.63 and after 0.60 Wmol/l)
(Table 2).
3.4. Antioxidant levels in plasma
The serum K-tocopherol levels in the CLA and in the con-
trol group subjects were unchanged, whereas the Q-tocopherol
levels in the CLA group increased signi¢cantly from the basal
level (0.10 mg/mmol) by 40% (P = 0.015) in the CLA-supple-
mented group (Table 2). No such increase was seen in the
control group (before 0.08 and after 0.09 mg/mmol).
4. Discussion
The main aim of this study was to investigate non-enzy-
matic and enzymatic lipid peroxidation in the body in CLA-
treated humans. Our study clearly shows that both 8-iso-
PGF2K and 15-keto-dihydro-PGF2K levels in the urine and
also the plasma levels of 8-iso-PGF2K were signi¢cantly ele-
vated indicating a direct e¡ect of CLA on in vivo lipid per-
oxidation. The 8-iso-PGF2K is formed in vivo in humans and
animals by free radical-catalysed oxidation of arachidonic
acid and is claimed to be a unique biomarker of non-enzy-
matic lipid peroxidation [14,15,20,22]. Increased amounts of
this compound are found both in the plasma and in the urine
in various human and animal models of oxidant injury or
dietary supplementation studies [15,17,19,26^29]. Measure-
ment of 15-keto-dihydro-PGF2K in peripheral plasma has
been applied in various species for many years as an indicator
of endogenous PGF2K secretion as a result of cyclooxygenase-
catalysed lipid peroxidation [13,16,21,30]. Recent studies on
15-keto-dihydro-PGF2K in urinary samples showed that mea-
surement of this metabolite in urinary samples could also
serve as a parameter of endogenous PGF2K release [21,29].
This study reports for the ¢rst time that CLA can upregu-
late both isoprostane and prostaglandin formation in humans.
This shows that CLA can modulate both free radical-induced
and cyclooxygenase-catalysed arachidonic acid oxidation. The
mechanism of induction of these two important biochemical
pathways cannot be determined from this study. Conjugated
linoleic acid has been proposed to a¡ect prostaglandin bio-
synthesis besides its anticarcinogenic and other bene¢cial
properties [8,9]. Prostaglandins have earlier been shown to
possess a cytotoxic e¡ect in cell growth [31]. In concert,
CLA-induced cytotoxicity in cancer cell lines has been shown
to be associated with increased lipid peroxidation [10,11].
Whether the increase of lipid peroxidation products in vivo
as demonstrated in this study is of importance for the anti-
tumorigenic e¡ect of CLA cannot be evaluated from this
study.
The total fat consumption was, also after addition of 4^5 g
extra fat, well within the range of a normal diet. Oleic acid
was used as a placebo control. Alternatively, linoleic acid
could have been used. The choice of placebo preparation
(oleic vs. linoleic acid) should be of no major importance
for the results regarding the increased lipid peroxidation after
CLA supplementation. We have earlier studied the e¡ect of
adding 3^4 times more linoleic acid in the context of a linoleic
acid-rich diet, and compared the e¡ects with those of a diet
enriched in oleic acid. There was no di¡erence in the urinary
concentration of F2-isoprostane between these diets [28].
Table 2
The levels and change (%) of 8-iso-PGF2K, 15-keto-dihydro-PGF2K, MDA and tocopherols in the body £uids in control and CLA-treated
groups
Control (n = 25) Change
(%)a
CLA (n = 28) Change
(%)a
P value for
di¡erence
between groupsBefore
(mean þ S.E.M.)
After
(mean þ S.E.M.)
Before
(mean þ S.E.M.)
After
(mean þ S.E.M.)
u-8-iso-PGF2K
(nmol/mmol
creatinine, morning)
0.33 þ 0.04 0.32 þ 0.04 8.3 0.47 þ 0.07 1.85 þ 0.35 407 0.0001
u-8-iso-PGF2K
(nmol/mmol
creatinine, 24 h)
0.34 þ 0.03 0.36 þ 0.04 17.0 0.50 þ 0.07 1.65 þ 0.29 333 6 0.0001
u-15-keto-dihydro-PGF2K
(nmol/mmol
creatinine, 24 h)
0.51 þ 0.07 0.54 þ 0.07 13.0 0.70 þ 0.09 1.30 þ 0.13 129 6 0.0001
p-MDA (Wmol/l) 0.63 þ 0.03 0.60 þ 0.03 30.7 0.60 þ 0.03 0.56 þ 0.03 1.8 n.s.
s-K-tocopherolb
(mg/mmol)
1.60 þ 0.02 1.60 þ 0.04 0.5 1.59 þ 0.05 1.59 þ 0.04 30.1 n.s.
s-K-tocopherolc
(Wmol/l)
26.2 þ 1.08 26.0 þ 0.96 30.1 25.0 þ 0.95 25.3 þ 1.1 1.0 n.s.
s-Q-tocopherolb
(mg/mmol)
0.08 þ 0.01 0.09 þ 0.01 6.4 0.10 þ 0.01 0.14 þ 0.01 40.2 0.015
s-Q-tocopherolc
(Wmol/l)
1.44 þ 0.11 1.49 þ 0.12 5.9 1.70 þ 0.07 2.33 þ 0.26 43.7 0.027
p = plasma, u = urine, s = serum, n.s. = non-signi¢cant, n = number of subjects in each group.
aPercent change is calculated as ((value after3value before)/value before)U100.
bLipid-corrected.
cWithout lipid correction.
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Although the levels of both 8-iso-PGF2K and 15-keto-dihy-
dro-PGF2K increased signi¢cantly, the relative increase was
much higher for 8-iso-PGF2K than for 15-keto-dihydro-
PGF2K. This indicates that CLA probably has a more direct
e¡ect on the non-enzymatic than on the enzymatic conversion
of arachidonic acid. The individual changes in the concentra-
tions of 15-keto-dihydro-PGF2K in the urine were signi¢cantly
correlated with those of 8-iso-PGF2K. It was recently shown
that intravenous administration of 8-iso-PGF2K may lead to
cyclooxygenase activation and subsequent prostaglandin F2K
formation in the rabbit (Basu, unpublished results). Thus,
formation of 8-iso-PGF2K after CLA treatment in this study
may possibly directly a¡ect the cyclooxygenases with sequen-
tial formation of PGF2K. However, the magnitude of the in-
crease of 8-iso-PGF2K and 15-keto-dihydro-PGF2K in this
study is not comparable to the earlier described in£ammatory
response-related [17,18] or oxidative injury-induced [19] for-
mation of these compounds.
The concentration of MDA in plasma, another lipid oxida-
tion indicator in vivo, did not increase after CLA treatment,
in contrast to urinary 8-iso-PGF2K and 15-keto-dihydro-
PGF2K. These results corroborate previously described com-
parisons of 8-iso-PGF2K and thiobarbituric acid reactive sub-
stances or MDA measurements in hydrogen peroxide- or car-
bon tetrachloride-induced lipid peroxidation studies
[19,28,32]. This is possibly because these two biomarkers of
lipid peroxidation re£ect di¡erent stages of lipid peroxidation
and/or insu⁄cient sensitivity to detect lipid peroxidation
products by measuring MDA in these experimental models.
Conjugated linoleic acid had no e¡ect on K-tocopherol. The Q-
tocopherol levels in the CLA group increased signi¢cantly.
In conclusion, dietary supplementation of CLA induces
both non-enzymatically and enzymatically catalysed lipid per-
oxidation in humans. The simultaneous measurement of 8-iso-
PGF2K and 15-keto-dihydro-PGF2K in body £uids opens ex-
cellent opportunities to study the role of non-enzymatic and
enzymatic lipid peroxidation in various human diseases and
dietary or therapeutic conditions. Further studies of the mech-
anism behind, and the possible consequences of, the increased
lipid peroxidation after CLA supplementation are urgently
needed.
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